Research overview
What is Larazotide Acetate?
Larazotide acetate is a short synthetic peptide investigated as a regulator of intestinal tight-junction signaling. Clinical development focused on oral administration in celiac disease, not a vial-based injectable application. The studied oral product and a separately sourced powder cannot be equated.
What has research examined?
A multicenter placebo-controlled trial enrolled 342 adults with persistent celiac symptoms despite a gluten-free diet. Some symptom outcomes favored the lowest studied larazotide group, but results were mixed across groups. A separate gluten-challenge trial found no significant difference from placebo in its primary urinary permeability ratio, despite differences in selected secondary immune markers.
Mixed trial endpoints and a formulation-specific oral study do not validate claims about an independently sourced vial or a general gut-healing treatment. This page does not recommend a regimen, preparation, or use.
Research references
- Larazotide acetate for persistent symptoms of celiac disease: randomized trialGastroenterology
- Larazotide during gluten challenge: randomized trialAlimentary Pharmacology & Therapeutics
Calculation boundary
Larazotide clinical trials studied an oral formulation and gut-specific endpoints. A generic powder-vial/U-100 visualization would misleadingly imply equivalence to those trial formulations.